Citations

Clear

479 citation(s) found for "Tobias, JS".

A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy
Kottschade, Lisa A. , Brys, Adam K. , Peikert, Tobias, Ryder, Mabel , Raffals, Laura E., Brewer, Jerry D., Markovic, Svetomir, Kottschade, Lisa, Raffals, Laura E. , Mosca, Paul J. , Markovic, Svetomir N. , Ryder, Mabel

Mayo Clinic

Melanoma Research | June 16, 2016 | Volume: 26 | Issue: 5 | Pages: 469-480

10.1097/cmr.0000000000000273 | PMID 27306502 Get It

Immune-related Adverse Events (irAEs) are the most significant toxicities associated with the use of checkpoint inhibitors, and result from disinhibition of the host’s immune homeostasis. The adverse effects experienced from immunotherapy are significantly different from those of chemotherapy and, to a lesser extent, targeted therapy. Early recognition and diagnosis of these toxicities is often challenging, but is critically important because of the potentially life-threatening nature and associated morbidity. Gastrointestinal, dermatologic, endocrine, and liver toxicities are the most commonly observed. Less commonly, the eyes, pancreas, kidneys, lungs, bone marrow, or nervous system may be affected. Although most irAEs may resolve with supportive care or discontinuation of drug, in severe cases, they may require hospitalization and immune suppressants, such as steroids, and/or may even cause death. The management of immune-related side effects requires a multidisciplinary approach.
Harnessing the Power of the Host: Improving Dendritic Cell Vaccines for Malignant Pleural Mesothelioma
Peikert, Tobias, Sterman, Daniel H.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 29, 2016 | Volume: 193 | Issue: 9 | Pages: 943-945

10.1164/rccm.201512-2444ed | PMID 27128703 Get It

Penile Prosthesis Surgery: Current Recommendations From the International Consultation on Sexual Medicine
Levine, Laurence A. , Becher, Edgardo, Bella, Anthony, Brant, William O. , Köhler, Tobias , Martínez‐Salamanca, Juan Ignacio , Trost, Landon , Morey, Allen F.

Mayo Clinic

The Journal of Sexual Medicine | March 25, 2016 | Volume: 13 | Issue: 4 | Pages: 489-518

10.1016/j.jsxm.2016.01.017 | PMID 27045255 Get It

ABSTRACT Introduction Penile prosthesis implantation has emerged as a definitive treatment to restore sexual function to the motivated man with erectile dysfunction. Substantial improvements in the design of inflatable devices have been made since they first became available more than four decades ago. Aim To review the history of the penile prosthesis, the indications, preoperative evaluation, and patient and partner satisfaction. The current approaches to addressing intra- and postoperative complications, provide an understanding of prosthesis infection, and placement of these devices will be reviewed. Methods A committee of worldwide experts in this field was assembled during the 2015 International Consultation on Sexual Medicine (ICSM) and performed a systematic review of the peer-reviewed published medical literature pertaining to penile prosthesis. Particular attention was given to higher level trials when available. Recommendations are based upon the Oxford Criteria. Main Outcome Measures Unfortunately there is limited level 1 and 2 evidence, and where expert opinion was utilized, the decision was unanimous within the committee with a goal of presenting a clinically relevant guideline pertaining to penile prostheses. Results Penile prosthesis has undergone an evolution over the past 40 years resulting in a more effective and reliable treatment for advanced erectile dysfunction not responding to less invasive methods including oral treatment with PDE5 inhibitors, vacuum erection device, and intracorporal injection therapy. It should be considered an appropriate treatment option for the man who wishes to restore erectile function and who understands the potential risk of mechanical failure and infection, both of which are less common now as a result of improvements made in device design as well as surgical protocols adhered to in the operating room. Patients must be clearly informed of the risks associated with penile prosthesis including mechanical failure, infection, shortening of the penis, change in sensation and configuration of the penis, as well as injury to local structures. Intraoperative complications are unusual but do occur and can usually be addressed intraoperatively to allow placement of the device at the time of initial surgery. Postoperative complications may also be addressed when they occur but may require more advanced reconstructive surgical techniques. Men with Peyronie's disease, corporal fibrosis due to infection, trauma, prior prosthesis explantation, priapism, and men who have undergone construction of a neophallus may require additional advanced maneuvers to obtain optimum results with a penile prosthesis. Conclusion Penile prosthesis remains as an important, viable, and effective treatment for male erectile dysfunction that does not respond to other less invasive approaches or when these approaches are contraindicated or not acceptable to the patient. These devices provide the patient with the ability to engage in penetrative sexual activity without interfering with urination, ejaculation, sensation, or orgasm. Although mechanical failure can occur, the current devices are more reliable as a result of design modifications. Infection remains the most dreaded complication but since the introduction of antibiotic and hydrophilic coatings, infection is less common. Overall, patient and partner satisfaction appear to be reasonably high when a penile prosthesis is used to restore erectile function.
Response to treatment in a prospective national infantile spasms cohort
Coryell, Jason , Nickels, Katherine , Ryan, Nicole, Leister, Erin, Loddenkemper, Tobias , Grinspan, Zachary M. , Hartman, Adam L. , Kossoff, Eric H. , Gaillard, William D. , Mytinger, John R. , Joshi, Sucheta M. , Shellhaas, Renée A. , Sullivan, Joseph , Dlugos, Dennis , Hamikawa, Lorie, Berg, Anne T. , Millichap, J Gordon , Knupp, Kelly G. , Nordli, Douglas R. , Wirrell, Elaine , Millichap, John , Shellhaas, Renée A , Gaillard, William D , Loddenkemper, Tobias , Berg, Anne T , Grinspan, Zachary , Nickels, Katherine C , Coryell, Jason

Mayo Clinic

Annals of Neurology | December 24, 2015 | Volume: 79 | Issue: 3 | Pages: 475-484

10.1002/ana.24594 | PMID 26704170 Get It

ObjectiveInfantile spasms are seizures associated with a severe epileptic encephalopathy presenting in the first 2 years of life, and optimal treatment continues to be debated. This study evaluates early and sustained response to initial treatments and addresses both clinical remission and electrographic resolution of hypsarrhythmia. Secondarily, it assesses whether response to treatment differs by etiology or developmental status.MethodsThe National Infantile Spasms Consortium established a multicenter, prospective database enrolling infants with new diagnosis of infantile spasms. Children were considered responders if there was clinical remission and resolution of hypsarrhythmia that was sustained at 3 months after first treatment initiation. Standard treatments of adrenocorticotropic hormone (ACTH), oral corticosteroids, and vigabatrin were considered individually, and all other nonstandard therapies were analyzed collectively. Developmental status and etiology were assessed. We compared response rates by treatment group using chi‐square tests and multivariate logistic regression models.ResultsTwo hundred thirty infants were enrolled from 22 centers. Overall, 46% of children receiving standard therapy responded, compared to only 9% who responded to nonstandard therapy (p < 0.001). Fifty‐five percent of infants receiving ACTH as initial treatment responded, compared to 39% for oral corticosteroids, 36% for vigabatrin, and 9% for other (p < 0.001). Neither etiology nor development significantly modified the response pattern by treatment group.InterpretationResponse rate varies by treatment choice. Standard therapies should be considered as initial treatment for infantile spasms, including those with impaired development or known structural or genetic/metabolic etiology. ACTH appeared to be more effective than other standard therapies. ANN NEUROL 2016;79:475–484
Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer
Mansfield, Aaron S. , Peikert, Tobias, Yi, Eunhee S. , Vasmatzis, George , Wigle, Dennis A. , Aubry, Marie Christine, Murphy, Stephen J. , Mansfield, Aaron S

Mayo Clinic

Clinical Cancer Research | December 14, 2015 | Volume: 22 | Issue: 9 | Pages: 2177-2182

10.1158/1078-0432.ccr-15-2246 | PMID 26667490 Get It

Abstract Purpose: The expression of programmed cell death ligand 1 (PD-L1) provides limited predictive value in identifying patients most likely to respond to immunotherapy. As the heterogeneity of PD-L1 expression may lead to sampling error and the misclassification of PD-L1 status, we assessed the distribution of PD-L1 expression in paired, resected multifocal lung cancers. Experimental Design: PD-L1 was assessed by IHC. Paired lesions were defined as independent primaries or related lesions using mate pair next-generation sequencing. Agreement statistics were used for analysis. Results: Sixty-seven multifocal lung cancers from 32 patients were sequenced and stained for PD-L1. There was agreement of PD-L1 expression by the tumor cells in paired lesions of 20 patients and disagreement of PD-L1 expression by the tumor cells in paired lesions of 12 patients (κ = 0.01). Sequencing identified that 23 patients had independent primary lung cancers and that 9 patients had related cancers. In paired lesions of patients with independent cancers, there was agreement of PD-L1 expression by the tumor cells in 12 patients and disagreement in 11 patients (κ = 0.31). In paired lesions of patients with related lung cancers, there was agreement of PD-L1 expression by the tumor cells in 8 patients and disagreement in 1 patient (κ = 0.73). Conclusions: The expression of PD-L1 is heterogeneous among paired independent lung cancers, but there are high levels of agreement in intrapulmonary metastasis. Clin Cancer Res; 22(9); 2177–82. ©2015 AACR.
Spontaneous Regression of Malignant Pleural Mesothelioma in a Patient with New-Onset Inflammatory Arthropathy
Moser, Justin C. , Peikert, Tobias, Roden, Anja C. , Midthun, David E. , Mansfield, Aaron S. , Mansfield, Aaron S

Mayo Clinic

Annals of the American Thoracic Society | September 15, 2015 | Volume: 12 | Issue: 9 | Pages: 1416-1417

10.1513/annalsats.201506-315le | PMID 26372807 Get It

Reply: Further Progress in Understanding Fibrosing Mediastinitis
Peikert, Tobias, Westerly, Blair, Specks, Ulrich

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | September 15, 2015 | Volume: 192 | Issue: 6 | Pages: 768-768

10.1164/rccm.201506-1183le | PMID 26371818 Get It

Noninvasive Computed Tomography–based Risk Stratification of Lung Adenocarcinomas in the National Lung Screening Trial
Maldonado, Fabien , Duan, Fenghai , Raghunath, Sushravya , Rajagopalan, Srinivasan, Karwoski, Ronald A., Greco, Erin, Nath, Hrudaya , Robb, Richard A., Bartholmai, Brian J. , Peikert, Tobias, Raghunath, Sushravya M, Garg, Kavita N. , Bartholmai, Brian J

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 8, 2015 | Volume: 192 | Issue: 6 | Pages: 737-744

10.1164/rccm.201503-0443oc | PMID 26052977 Get It

Abstract Rationale Screening for lung cancer using low-dose computed tomography (CT) reduces lung cancer mortality. However, in addition to a high rate of benign nodules, lung cancer screening detects a large number of indolent cancers that generally belong to the adenocarcinoma spectrum. Individualized management of screen-detected adenocarcinomas would be facilitated by noninvasive risk stratification. Objectives To validate that Computer-Aided Nodule Assessment and Risk Yield (CANARY), a novel image analysis software, successfully risk stratifies screen-detected lung adenocarcinomas based on clinical disease outcomes. Methods We identified retrospective 294 eligible patients diagnosed with lung adenocarcinoma spectrum lesions in the low-dose CT arm of the National Lung Screening Trial. The last low-dose CT scan before the diagnosis of lung adenocarcinoma was analyzed using CANARY blinded to clinical data. Based on their parametric CANARY signatures, all the lung adenocarcinoma nodules were risk stratified into three groups. CANARY risk groups were compared using survival analysis for progression-free survival. Measurements and Main Results A total of 294 patients were included in the analysis. Kaplan-Meier analysis of all the 294 adenocarcinoma nodules stratified into the Good, Intermediate, and Poor CANARY risk groups yielded distinct progression-free survival curves (P &lt; 0.0001). This observation was confirmed in the unadjusted and adjusted (age, sex, race, and smoking status) progression-free survival analysis of all stage I cases. Conclusions CANARY allows the noninvasive risk stratification of lung adenocarcinomas into three groups with distinct post-treatment progression-free survival. Our results suggest that CANARY could ultimately facilitate individualized management of incidentally or screen-detected lung adenocarcinomas.